论文部分内容阅读
目的:探讨不同剂量的厄贝沙坦治疗高原心脏病(high altitude heart disease,HAHD)伴心力衰竭的临床疗效和安全性。方法:选择高原性心脏病伴心力衰竭患者42例,随机分为A、B两组,A组给厄贝沙坦150mg/日,B组给厄贝沙坦300mg/日,治疗前后分别统计心功能分级和检测右室Tei指数、收缩压(SBP)、舒张压(DBP)水平。结果:心功能改善治疗前后比较两组均有统计学差异,B组心功能改善优于A组,右室Tei指数治疗前后比较两组均有统计学差异,B组右室Tei指数降低优于A组。血压治疗前后比较A组(DBP)及B组SBP)和(DBP)均有显著统计学差异,同时不同剂量的厄贝沙坦对血压的影响有显著统计学差异,B组出现低血压和分水岭脑梗死(CWI)各1例。结论:厄贝沙坦治疗HAHD伴心力衰竭在心功能改善方面疗效确切,且疗效与药物剂量正相关,但随着厄贝沙坦剂量的增加安全性也随之降低。
Objective: To investigate the clinical efficacy and safety of different doses of irbesartan in the treatment of high altitude heart disease (HAHD) with heart failure. Methods: Forty-two patients with heart failure and heart failure were randomly divided into A and B groups. A group received irbesartan 150 mg / day, and B group received irbesartan 300 mg / day, respectively, before and after treatment Function classification and detection of right ventricular Tei index, systolic blood pressure (SBP), diastolic blood pressure (DBP) levels. Results: Before and after the improvement of cardiac function, there were significant differences between the two groups. The improvement of cardiac function in group B was better than that of group A. The Tei index of right ventricle before and after treatment was significantly different in both groups. The decrease of right ventricular Tei index in group B was better than that of group A Group A Blood pressure before and after treatment compared group A (DBP) and group B SBP) and (DBP) were statistically significant differences in different doses of irbesartan on blood pressure were significantly different, group B hypotension and watershed One case of cerebral infarction (CWI). Conclusion: Irbesartan in treatment of HAHD with heart failure has definite curative effect in improving cardiac function, and the curative effect is positively correlated with the dosage of irbesartan. However, with the increase of irbesartan dosage, safety is also reduced.